La vendita allo scoperto per Tactile Systems Tech dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Tactile Systems Tech. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Tactile Systems Tech (NASDAQ:TCMD) Azioni, Report sulle vendite allo scoperto

Tactile Systems Tech

Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.

Tactile Systems Technology, Inc. - Common Stock

Tactile Systems Technology Inc

RBC Capital analyst Mike Dahl downgrades Installed Building Prods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBP#NYSE">IBP</a>) from Sector Perform to Underperform and lowers the price target from $203 to $197.

News

Downgrades

Price Target

Analyst Ratings

RBC Capital Downgrades Installed Building Prods to Underperform, Lowers Price Target to $197

Earnings

Earnings Beats

TELUS Q3 2024 Adj. EPS C$0.28 Beats C$0.23 Estimate, Sales C$5.099B Beat C$5.050B Estimate

TELUS Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIXT#NYSE">TIXT</a>) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.01 by 400 percent. This is a 73.68 percent decrease over earnings of $0.19 per share from the same period last year. The company reported quarterly sales of $658.00 million which beat the analyst consensus estimate of $647.14 million by 1.68 percent. This is a 0.75 percent decrease over sales of $663.00 million the same period last year.

TIXT

TELUS Intl Q3 2024 Adj EPS $0.05 Beats $0.01 Estimate, Sales $658.00M Beat $647.14M Estimate

Marcus & Millichap Earlier Reported Q3 EPS $(0.14) Beats $(0.19) Estimate, Sales $168.51M Beat $160.90M Estimate

Raymond James analyst Robert Dodd downgrades WhiteHorse Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHF#NASDAQ">WHF</a>) from Outperform to Market Perform.

Raymond James Downgrades WhiteHorse Finance to Market Perform

Earnings Misses

Brookfield Bus Partners Q3 2024 EPS $1.39, Revenues $9.232B

RBC Capital analyst Leonid Timashev initiates coverage on Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Outperform rating and announces Price Target of $80.

Initiation

CYTK

RBC Capital Initiates Coverage On Cytokinetics with Outperform Rating, Announces Price Target of $80

Adjusted EBITDA is expected to be in the range of $880 million to $920 million. Capital expenditures are expected to be approximately $250 million.

Guidance

Advanced Drainage Systems Cuts FY25 Net Sales Outlook From $2.925B - $3.025B To $2.900B - $2.975B,  Est $2.985B

Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) said on Thursday after market close that it is on track to turn a gross profit in the fourth quarter despite a<a href="https://www.benzinga.com/news/24/10/41223011/rivians-production-guidance-cut-spurred-by-miscommunication-with-atlanta-based-supplier-resulting-in"> production disruption flagged earlier this year.</a>
What Happened: The EV maker on Thursday also reaffirmed its 2024 delivery outlook of 50,5000 to 52,000 vehicles for the full year, helping relieve investor worries.
Rivian cut its annual production forecast last month by as much as 18% to between 47,000 and 49,000 electric vehicles, citing production disruption owing to a component shortage. However, the production disruption will not seemingly impact the company&#8217;s delivery targets for the year. 
For the third quarter, the EV startup <a href="https://www.benzinga.com/news/earnings/24/11/41825787/rivian-q3-earnings-highlights-revenue-eps-miss-ceo-confident-in-q4-gross-profit-r2-being-fundamenta">reported revenue of $874 million</a>, which missed a Street consensus estimate of $1.00 billion, and a loss of 99 cents per share, missing a Street consensus loss of 92 cents per share. 
The company also announced a five-year strategic supply agreement for batteries with&nbsp;LG Energy Solutions for its R2 SUV, slated for launch in the first half of 2026. 
Why It Matters: Rivian produced 13,157 vehicles in the third quarter and delivered 10,018 vehicles. Currently, the company has only two vehicles in production- the R1T truck and the R1S SUV with a starting price of around $70,000. 
The company is looking to expand its total addressable market with the R2 SUV expected to be priced around $45,000, in the same price range as Tesla Inc&#8217;s best-selling Model Y SUV. 
The company is also planning to start deliveries of its<a href="https://www.benzinga.com/news/24/03/37552684/rivian-almost-catches-up-to-teslas-ev-lineup-with-new-r2-r3-but-theres-no-cybertruck-fighter-yet"> R3 crossover after the R2.</a> The crossover is expected to be priced lower than the R2 SUV but it is unclear whether the R3's price will undercut the Tesla Model 3 or remain within the same range.
Price Action: Rivian shares closed up 3.35% at $10.04 on Thursday. The stock is down 52.4% year-to-date, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. 
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41803756/xpeng-flying-car-can-be-mastered-in-3-hours-says-company-chairman" target="_blank" rel="noreferrer noopener">XPeng Flying Car Can Be Mastered In 3 Hours, Says Company Chairman</a></li>
</ul>
Image via Shutterstock

Tech

General

RIVN

Rivian Says It Is On Track For 2024 Delivery Targets Despite Production Challenges

Hippo Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIPO#NYSE">HIPO</a>) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.95) by 64.21 percent. The company reported quarterly sales of $95.500 million which beat the analyst consensus estimate of $94.064 million by 1.53 percent. This is a 65.51 percent increase over sales of $57.700 million the same period last year.

HIPO

Hippo Holdings Q3 2024 GAAP EPS $(0.34) Beats $(0.95) Estimate, Sales $95.500M Beat $94.064M Estimate

Macquarie analyst Paul Golding downgrades Planet Fitness (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLNT#NYSE">PLNT</a>) from Outperform to Neutral and raises the price target from $91 to $99.

PLNT

Macquarie Downgrades Planet Fitness to Neutral, Raises Price Target to $99

Fiscal 2025 Outlook
The Company's outlook for 2025 was updated as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">(as of November 8, 2024)</td>
<td colspan="1" rowspan="1">Updated Fiscal 2025 Guidance</td>
<td colspan="1" rowspan="1">Previous Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Sales</td>
<td colspan="1" rowspan="1">$200 million to $210 million</td>
<td colspan="1" rowspan="1">$200 million to $210 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Gross Margin</td>
<td colspan="1" rowspan="1">23% to 24% of sales</td>
<td colspan="1" rowspan="1">22% to 23% of sales</td>
</tr>
<tr>
<td colspan="1" rowspan="1">SG&amp;A expense (including amortization)(1)</td>
<td colspan="1" rowspan="1">17.0% to 18.0% of sales</td>
<td colspan="1" rowspan="1">16.5% to 17.5% of sales</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA(2)</td>
<td colspan="1" rowspan="1">$18.0 million to $21.0 million</td>
<td colspan="1" rowspan="1">$16.5 million to $19.5 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Effective Tax Rate</td>
<td colspan="1" rowspan="1">20% to 22%</td>
<td colspan="1" rowspan="1">20% to 22%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Capital Expenditures</td>
<td colspan="1" rowspan="1">$13.0 million to $18.0 million</td>
<td colspan="1" rowspan="1">$10.0 million to $15.0 million</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">(1)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Includes approximately $6.5 million to $7.5 million of BN supplemental performance bonus, equity-based compensation, and ERP conversion costs included in SG&amp;A expense.</td>
</tr>
</tbody>
</table>
</figure>

Graham Reaffirms 2025 Net Sales Outlook Of $200M-$210M Vs. $205.40M Est.; Raises Gross Margin Guidance To 23%-24% From 22%-23% And Adj. EBITDA To $18M-$21M From $16.5M-$19.5M

Embraer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERJ#NYSE">ERJ</a>) reported quarterly earnings of $1.20 per share which beat the analyst consensus estimate of $0.60 by 100 percent. The company reported quarterly sales of $1.69 billion which beat the analyst consensus estimate of $1.59 billion by 6.34 percent. This is a 31.73 percent increase over sales of $1.28 billion the same period last year.

Embraer-Empresa Brasileira De Aeronautica

Embraer Q3 2024 Adj EPS $1.20 Beats $0.60 Estimate

Keybanc analyst Scott Schoenhaus upgrades Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) from Sector Weight to Overweight and announces $70 price target.

Upgrades

DOCS

Keybanc Upgrades Doximity to Overweight, Announces $70 Price Target

DCBO

Docebo Raises FY24 Outlook: Sees Total Revenue Growth Of Approximately 19.5% (Prior View: 18.0%-19.0%), Adjusted EBITDA As A Percentage Of Total Revenue Of Approximately 15.5%

Advanced Drainage Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMS#NYSE">WMS</a>) reported quarterly earnings of $1.70 per share which missed the analyst consensus estimate of $1.90 by 10.53 percent. This is a 0.58 percent decrease over earnings of $1.71 per share from the same period last year. The company reported quarterly sales of $782.61 million which missed the analyst consensus estimate of $822.35 million by 4.83 percent. This is a 0.31 percent increase over sales of $780.22 million the same period last year.

Advanced Drainage Systems Q2 2025 Adj EPS $1.70 Misses $1.90 Estimate, Sales $782.61M Miss $822.35M Estimate

Management expects subscription revenue to grow about two percentage points higher than overall company revenue while professional services revenue to be down sequentially from Q3.

Docebo Sees Q4 Revenues Of $56M-$56.2M Vs. $56.02M Estimate; Adjusted EBITDA Margin Of 16.5%-16.7%

Raymond James analyst Justin Jenkins downgrades EnLink Midstream (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENLC#NYSE">ENLC</a>) from Outperform to Market Perform.

ENLC

Raymond James Downgrades EnLink Midstream to Market Perform

Full-year 2024 Adjusted EBITDA Guidance Remains Unchanged At A Range Of $220 Million To $240 Million.

FTRE

Fortrea Narrows FY24 Revenue Guidance From $2.70B - $2.75B To $2.70B - $2.725B, Est $2.697B

2024 Financial Guidance
Management reiterates its full year 2024 guidance:
<ul>
<li>Anticipated Total Net Revenues expected to be between $87 million and $95 million;</li>
<li>Anticipated Operating Expenses expected to remain between $115 million and $120 million;</li>
<li>Anticipated Total Annual Cash Investment expected to remain between $15 million and $20 million; and</li>
<li>Cash and Cash Equivalents anticipated to continue to support operations as currently planned into 2027.</li>
</ul>

Biotech

Health Care

YMAB

Y-mAbs Anticipates 2024 Total Net Revenues Of $87M-$95M Vs. Consensus Of $91.67M

Oppenheimer analyst Suraj Kalia maintained a Buy rating on Tactile Systems Technology (TCMD – Research Report) today and set a price target of $20....

Oppenheimer Remains a Buy on Tactile Systems Technology (TCMD)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ginkgo Bioworks Holdings (DNA – Research Report), BioMarin Pharma...

Analysts Offer Insights on Healthcare Companies: Ginkgo Bioworks Holdings (DNA), BioMarin Pharmaceutical (BMRN) and Tactile Systems Technology (TCMD)

Every investor hopes to uncover a growth stock, an equity poised for rapid appreciation and substantial long-term returns. The real challenge lies ...

These 2 'Strong Buy' Medical Device Stocks Are Poised for Growth, Says Analyst

Tactile Systems Technology GAAP EPS of $0.21 beats by $0.03, revenue of $73.09M misses by $2.92M

Tactile Systems Technology, Inc. (TCMD) Q3 2024 Earnings Call Transcript

Tactile Systems Technology ( ($TCMD) ) has released its Q3 earnings. Here is a breakdown of the information Tactile Systems Technology presented to...

Tactile Systems Technology Reports Q3 2024 Results, Launches Share Buyback

BTIG downgraded Tactile Systems (TCMD) to Neutral from Buy without a price target following the Q3 report. While the shares are inexpensive and Tac...

Tactile Systems downgraded to Neutral from Buy at BTIG

In a report released today, Adam Maeder from Piper Sandler maintained a Buy rating on Tactile Systems Technology (TCMD – Research Report), with a p...

Piper Sandler Sticks to Their Buy Rating for Tactile Systems Technology (TCMD)

Tactile Systems cut to Neutral at BTIG after Q3 revenue miss

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.&nbsp; 1. STOCK NEWS: Boeing's (BA) machinist union ha...

Comments

Tactile Systems Tech

Vendite allo scoperto

Tactile Systems Tech (NASDAQ:TCMD) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO